Lucid Diagnostics Investor Relations Material
Latest events
Q4 2024
Lucid Diagnostics
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Lucid Diagnostics Inc
Access all reports
Lucid Diagnostics Inc. is a medical diagnostics company focused on the early detection of esophageal precancer and cancer. The company develops and commercializes diagnostic tests that aim to identify patients at risk of esophageal adenocarcinoma, a cancer often associated with gastroesophageal reflux disease (GERD) and Barrett’s esophagus. Lucid's lead product, the EsoCheck diagnostic device, is designed to collect esophageal cells in a non-invasive procedure for further analysis using its EsoGuard test, which detects genetic changes associated with cancer risk. The company’s technology provides a less invasive alternative to traditional diagnostic methods like endoscopy. The company is headquartered in New York, New York, and its shares are listed on the NASDAQ.
Latest articles
)
Lowe's Companies: Building a One-Stop Shop for Home Improvement
Lowe's Companies began as a single store in 1921 and has steadily expanded its footprint and offerings, now operating 1,750 stores across the U.S.
7 May 2025
)
Greg Abel: Succeeding Warren Buffett at Berkshire Hathaway
After decades working with Warren Buffett and Charlie Munger, Greg Abel was named Buffett’s successor as he steps down in late 2025.
5 May 2025
)
Intuitive Surgical: Enhancing Surgery with Robotic Precision
Intuitive Surgical has revolutionized surgery with robotics, building its dominant position through decades of innovation, validation, and expansion.
2 May 2025
Ticker symbol
LUCD
Country
🇺🇸 United States